Wang et al. reported that forkhead box protein A2 (FOXA2) overexpression was found to amplify the effectiveness of lenvatinib on HCC cells by upregulating the AMPK-mTOR-autophagy signaling pathway 53. Here, MTOR is linked to hepatocellular carcinoma.